Details of the Drug Combination

General Information of Drug Combination (ID: DCWQIFH)

Drug Combination Name
NABILONE Oxyphenbutazone
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs NABILONE   DMVRYT2 Oxyphenbutazone   DMPZS7U
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 21.77
Bliss Independence Score: 21.77
Loewe Additivity Score: 26.48
LHighest Single Agent (HSA) Score: 26.48

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of NABILONE
Disease Entry ICD 11 Status REF
Insomnia 7A00-7A0Z Approved [2]
NABILONE Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Inhibitor [3]
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
NABILONE Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cannabinoid receptor 2 (CNR2) OTYP9P43 CNR2_HUMAN Affects Binding [4]
------------------------------------------------------------------------------------
Indication(s) of Oxyphenbutazone
Disease Entry ICD 11 Status REF
Arthritis FA20 Approved [2]
Oxyphenbutazone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serum albumin (ALB) TTFNGC9 ALBU_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Oxyphenbutazone Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [6]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
4 Cloning and pharmacological characterization of the dog cannabinoid CB?receptor. Eur J Pharmacol. 2011 Nov 1;669(1-3):24-31. doi: 10.1016/j.ejphar.2011.08.002. Epub 2011 Aug 19.
5 Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
6 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.